WallStSmart

Milestone Scientific (MLSS)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 36076% more annual revenue ($3.22B vs $8.90M). WST leads profitability with a 16.9% profit margin vs -51.3%. WST earns a higher WallStSmart Score of 65/100 (C+).

MLSS

Avoid

16

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: -24.40

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MLSSUndervalued (+72.0%)

Margin of Safety

+72.0%

Fair Value

$0.95

Current Price

$0.39

$0.56 discount

UndervaluedFair: $0.95Overvalued
WSTSignificantly Overvalued (-56.0%)

Margin of Safety

-56.0%

Fair Value

$157.79

Current Price

$314.50

$156.71 premium

UndervaluedFair: $157.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MLSS0 strengths · Avg: 0/10

No standout strengths identified

WST5 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

MLSS4 concerns · Avg: 3.5/10
Price/BookValuation
13.0x4/10

Trading at 13.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$33.90M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
44.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MLSS

MLSS has a balanced fundamental profile.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : MLSS

The primary concerns for MLSS are Price/Book, EPS Growth, Market Cap.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.

Key Dynamics to Monitor

MLSS profiles as a turnaround stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (65/100 vs 16/100), backed by strong 16.9% margins and 21.0% revenue growth. MLSS offers better value entry with a 72.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Milestone Scientific

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Milestone Scientific, Inc. develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States, China, and internationally. The company is headquartered in Livingston, New Jersey.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?